Lineage Cell Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lineage Cell Therapeutics Inc 's ROA in the second quarter of 2026?
Lineage Cell Therapeutics Inc recorded a cumulative net loss of $-32 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -30.72%.

However, within the Healthcare sector 426 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4066, from total ROA ranking in the first quarter of 2026 at 4725.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	17.01 %	-1.99 %	-0.56 %	-7.2 %	-11.68 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-32	-64	-63	-68	-41
Return On Assets (TTM)	-30.72 %	-63.61 %	-62.62 %	-66.61 %	-39.54 %
LCTX's Total Ranking	# 4066	# 4725	# 4182	# 3939	# 3504
Total Assets (TTM) in million	106	110	113	90	91
Seq. Total Assets Change	-3 %	-2.71 %	25.6 %	-1.28 %	-18.75 %
Seq. Net Income Change	-	-	-	-	-

LCTX's 5 Years Annual ROA >> Back to LCTX Management Effectiveness >> Compare LCTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 44
Sector	# 427
Overall	# 3615

Return On Assets Statistics
High	Average	Low
59.79 %	-39.7 %	-129.22 %
(Mar 31 2017)		(Dec 31 2013)

Financial Statements
Lineage Cell Therapeutics Inc 's Assets	$ 106 million	LCTX's Balance sheet
Lineage Cell Therapeutics Inc 's Income	$ 2 million	Quarterly LCTX's Income Statement
LCTX's Income by Division		See LCTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-0.56 %	12.08 %	-18.31 %	-29.15 %	61.69 %
Total Assets in million	113	113	101	124	175
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-63	-19	-21	-26	-43
Annual Return On Assets	-56.28 %	-16.41 %	-21.26 %	-21.31 %	-24.79 %

LCTX's 5 Years Annual ROA >> Back to LCTX Management Effectiveness >> Compare LCTX ROA to its Competitors

More Return On Assets Ratios
LCTX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LCTX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LCTX's Competitors
Subscribers only: Roa for Lineage Cell Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for LCTX's Customers

You may also want to know
LCTX's Roi	LCTX's Inventory Turnover Ratio	LCTX's Growth Rates	LCTX's Dividend Comparisons
	LCTX's Profitability Ratios	LCTX's Asset Turnover Ratio	LCTX's Dividend Growth
LCTX's Roe	LCTX's Valuation Ratios	LCTX's Financial Strength Ratios	LCTX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T18:37:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.